Showing 2461-2470 of 3068 results for "".
- New Serum Targets Menopausal Skin Changes with Plant-Based Technologyhttps://modernaesthetics.com/news/new-serum-targets-menopausal-skin-changes-with-plant-based-technology/2483594/In recognition of Menopause Awareness Month, skinbetter science® announced the release of Mystro Revive Renewing Serum, a new topical product aimed at addressing visible skin changes associated with perimenopause and menopause.
- Study Evaluates Ready-To-Use Botox for Lateral Canthal, Glabellar Lines Treatmenthttps://modernaesthetics.com/news/study-evaluates-ready-to-use-botox-for-lateral-canthal-glabellar-lines-treatment/2483549/Newly published research in Dermatologic Surgery found liquid nivobotulinumtoxinA was effective and well-tolerated in treating moderate-to-severe lateral canthal lines (LCLs) and glabellar lines (GLs). Jean Carruthers, MD, FRCSC, FRC, co-authored the study, titled “NivobotulinumtoxinA in
- Sciton Launches Multi-Wavelength Resurfacing Laser Platformhttps://modernaesthetics.com/news/sciton-launches-multi-wavelength-resurfacing-laser-platform/2483427/Sciton, Inc. has introduced HALO® TRIBRID™, a laser platform that integrates 3 wavelengths—2940 nm, 1927 nm, and 1470 nm—into a single resurfacing device. The system combines the company’s previously distinct technologies (HALO®, MOXI™, and Erbium Resurfacing) into one handpiece, allowing provide
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- Neuvian Skincare Granted US Patent for Dual-Peptide Complexhttps://modernaesthetics.com/news/neuvian-skincare-granted-us-patent-for-dual-peptide-complex/2483373/Neuvian Skincare has received a US patent for its dual-peptide formulation targeting inflammatory skin conditions such as wounds, scars, and eczema, according to a press release. The patent (No. 12,377,156 B2), issued for “Compositions and Methods for Treatment of Wounds and Inflammatory Skin Con
- Study Links Personality Traits to Rhinoplasty Satisfactionhttps://modernaesthetics.com/news/study-links-personality-traits-to-rhinoplasty-satisfaction/2483320/A new study published in Aesthetic Plastic Surgery suggests a distinct relationship between personality traits and satisfaction with rhinoplasty outcomes. The study, titled “Rhinoplasty and the ‘Big Five’ Model: The Impact of Patients’ Personality Traits on Post-surgical Satisfac
- Thermage® FLX Exceeds 5 Million Skin Tightening Treatmentshttps://modernaesthetics.com/news/thermage-flx-exceeds-5-million-skin-tightening-treatments/2483284/Solta Medical, a subsidiary of Bausch Health Companies Inc., announced that more than 5 million Thermage® treatments have been performed worldwide, underscoring the global uptake of its skin tightening technology. Thermage® uses monopolar radiofrequency energy to heat skin layers and stimu
- Revance Brings Mepivacaine-Based Fillers to US Markethttps://modernaesthetics.com/news/revance-brings-mepivacaine-based-fillers-to-us-market/2483155/Revance has announced the US launch of the Teoxane RHA® Collection with Mepivacaine, marking a significant innovation in dermal filler formulations. The update reflects a shift in anesthetic agents used in hyaluronic acid fillers, with mepivacaine replacing lidocaine as the primary ane
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe
- Device Manufacturer’s Initiative Offers Treatments to Support Firefighters’ Healthhttps://modernaesthetics.com/news/device-manufacturers-initiative-offers-treatments-to-support-firefighters-health/2483123/BTL Industries has launched a nationwide initiative aimed at addressing the mental and physical health challenges faced by firefighters, particularly those serving in high-risk wildfire regions. The program is framed under BTL’s Heros Deserve Healing campaign, which calls on clinicians an